import type { Metadata } from "next";
import Link from "next/link";
import { notFound } from "next/navigation";
import Footer from "../../components/Footer";
import WaitlistForm from "../../components/WaitlistForm";

interface ArticleSection {
  heading: string;
  body: string[];
}

interface Article {
  title: string;
  description: string;
  date: string;
  readTime: string;
  relatedSlugs: string[];
  sections: ArticleSection[];
}

const articles: Record<string, Article> = {
  "natural-glp1-activation": {
    title: "Natural GLP-1 Activation: What the Research Shows",
    description:
      "AMPK activation in intestinal L-cells stimulates endogenous GLP-1 secretion. A review of the clinical evidence behind natural incretin production and what it means for metabolic support.",
    date: "2026-02-20",
    readTime: "8 min",
    relatedSlugs: ["nanoemulsion-vs-capsules", "endogenous-vs-exogenous-glp1"],
    sections: [
      {
        heading: "The AMPK pathway and GLP-1 production",
        body: [
          "AMP-activated protein kinase (AMPK) is a master regulator of cellular energy metabolism. When activated in intestinal L-cells, AMPK triggers a signaling cascade that increases the transcription and secretion of GLP-1 (glucagon-like peptide-1), the same incretin hormone targeted by pharmaceutical drugs like semaglutide and tirzepatide.",
          "This pathway is distinct from nutrient-stimulated GLP-1 release. AMPK-driven secretion can amplify GLP-1 output beyond what food intake alone produces, opening a non-pharmaceutical route to incretin modulation.",
        ],
      },
      {
        heading: "How natural compounds stimulate GLP-1 secretion",
        body: [
          "GLP-1 is an incretin hormone secreted by L-cells in the small intestine after food intake. It signals the brain to reduce appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The pharmaceutical GLP-1 drug class works by injecting synthetic versions of this hormone at supraphysiological doses.",
          "Certain GRAS-certified compounds activate AMPK in intestinal L-cells, triggering endogenous GLP-1 secretion through the body's own production machinery. Multiple randomized controlled trials have demonstrated statistically significant increases in postprandial GLP-1 levels with AMPK-activating compounds compared to placebo.",
          "Parallel pathways contribute to the effect. GPR120 receptor activation and insulin receptor sensitization each stimulate GLP-1 through distinct but complementary mechanisms. The combination addresses multiple nodes on the same biological pathway.",
        ],
      },
      {
        heading: "Clinical evidence for natural metabolic modulation",
        body: [
          "AMPK-activating compounds have a robust body of clinical evidence supporting their effects on metabolic parameters. Meta-analyses of randomized controlled trials have found significant effects on fasting blood glucose, HbA1c, total cholesterol, LDL cholesterol, and triglycerides.",
          "The GLP-1-specific effects are a more recent area of investigation. The identification of AMPK-mediated GLP-1 secretion as a primary mechanism has reframed these metabolic effects within the incretin pathway, connecting them to the same biological system targeted by the GLP-1 drug class.",
          "This does not mean the effects are equivalent to pharmaceutical GLP-1 agonists. The magnitude is different. The mechanism is different. But the pathway is the same, and the clinical evidence supporting the upstream activation of that pathway is real and growing.",
        ],
      },
      {
        heading: "Bioavailability: the limiting factor",
        body: [
          "The primary challenge with oral metabolic compounds is bioavailability. Many AMPK activators have absolute oral bioavailability below 10%, meaning the majority of an ingested dose never reaches systemic circulation. Poor absorption across the intestinal membrane and extensive first-pass hepatic metabolism are the main bottlenecks.",
          "This low bioavailability is why standard oral formats, despite containing adequate doses, produce inconsistent results. A compound may show strong effects in controlled trials where delivery is optimized, but in a standard capsule or tablet, most of the active compound is lost before reaching its target pathways.",
          "Nanoemulsion delivery systems address this limitation by encapsulating active compounds in lipid-based nanoparticles (20-200nm). This increases surface area for absorption, protects compounds from enzymatic degradation in the GI tract, and enhances transcellular transport across the intestinal epithelium.",
        ],
      },
      {
        heading: "Safety and drug interaction considerations",
        body: [
          "The compounds used in natural GLP-1 activation formulas carry GRAS (Generally Recognized as Safe) status and have well-documented safety profiles at standard dosages. The most common side effects are mild gastrointestinal symptoms, particularly when initiating a new regimen.",
          "The primary safety concern is drug interactions. Some AMPK-activating compounds inhibit cytochrome P450 enzymes (CYP2D6, CYP2C9, CYP3A4), which metabolize many prescription medications. They can also potentiate the effects of blood sugar-lowering drugs.",
          "Anyone taking prescription medication should consult their healthcare provider before starting any new regimen. This applies to any compound with documented metabolic activity, regardless of its regulatory classification.",
        ],
      },
    ],
  },

  "nanoemulsion-vs-capsules": {
    title: "Nanoemulsion vs. Capsules: Why Delivery Format Matters",
    description:
      "Most oral supplements fail at absorption. Nanoemulsion technology encapsulates active compounds in lipid-based nanoparticles, dramatically improving bioavailability compared to standard capsules and tablets.",
    date: "2026-02-14",
    readTime: "7 min",
    relatedSlugs: ["natural-glp1-activation", "natural-dpp4-inhibition"],
    sections: [
      {
        heading: "The bioavailability problem in oral supplements",
        body: [
          "Bioavailability refers to the proportion of an ingested substance that reaches systemic circulation in an active form. For most oral supplements, this number is surprisingly low. Compounds degrade in stomach acid, fail to cross the intestinal membrane efficiently, or are metabolized by the liver before reaching their target tissues.",
          "This creates a gap between what clinical research demonstrates and what consumers experience. A compound may show strong effects in a controlled trial where dosing, timing, and formulation are optimized, but when the same compound is compressed into a standard capsule or tablet and sold over the counter, the results are often inconsistent or absent.",
          "The supplement industry has historically addressed this problem by increasing dosage. If bioavailability is 5%, increase the dose twentyfold. This approach has obvious limitations: larger pills, more excipients, greater GI side effects, and a ceiling on what can be practically delivered in a single dose.",
        ],
      },
      {
        heading: "What is nanoemulsion technology?",
        body: [
          "A nanoemulsion is a colloidal dispersion of two immiscible liquids (typically oil and water) stabilized by surfactants, with droplet sizes in the 20-200 nanometer range. In the context of supplement delivery, it means encapsulating active compounds in lipid-based nanoparticles that are small enough to be readily absorbed across the intestinal epithelium.",
          "The key advantages over standard oral formats are threefold. First, the dramatically increased surface area (a function of particle size) means more compound is exposed to absorptive surfaces. Second, the lipid coating protects the compound from enzymatic degradation in the GI tract. Third, lipid-based nanoparticles can exploit natural lipid absorption pathways to enhance transcellular transport.",
          "Unlike some nanotechnology applications that require complex manufacturing processes, nanoemulsions can be produced using high-pressure homogenization or microfluidization, making them scalable for commercial production while maintaining consistent particle size distribution.",
        ],
      },
      {
        heading: "Nanoemulsion vs. liposomal delivery",
        body: [
          "Liposomal delivery is another lipid-based approach that has gained popularity in the supplement market. Liposomes are spherical vesicles with a phospholipid bilayer surrounding an aqueous core. They can encapsulate both hydrophilic (water-soluble) and hydrophobic (fat-soluble) compounds.",
          "Nanoemulsions and liposomes share the principle of lipid-based encapsulation but differ in structure and performance characteristics. Nanoemulsions are thermodynamically stable oil-in-water (or water-in-oil) systems, while liposomes are metastable structures that can fuse, aggregate, or leak over time. This gives nanoemulsions a practical advantage in shelf stability and batch-to-batch consistency.",
          "For the specific compounds used in GLP-1 activation formulas, nanoemulsion was selected over liposomal delivery because of superior physical stability, more consistent particle size distribution, and better compatibility with the hydrophobic nature of the active compounds.",
        ],
      },
      {
        heading: "Why the liquid format is required",
        body: [
          "A common question about nanoemulsion supplements is why they cannot be delivered as a capsule or tablet. The answer is structural. Compressing a nanoemulsion into a dry format would destroy the nanoparticle architecture that makes it effective. The lipid-based droplets require an aqueous phase to maintain their size, stability, and surface properties.",
          "The liquid format also eliminates the dissolution step required by tablets and capsules. When a standard supplement is swallowed, it must first disintegrate, then dissolve, before any absorption can occur. This process adds time and introduces variability. A liquid nanoemulsion bypasses disintegration and dissolution entirely, presenting the active compounds in a pre-solubilized, immediately absorbable form.",
        ],
      },
      {
        heading: "Implications for supplement efficacy",
        body: [
          "The difference between a standard capsule and a nanoemulsion delivery system is not incremental. Published research on nanoemulsion-enhanced bioavailability reports improvements ranging from 3x to 10x or more, depending on the specific compound and formulation parameters.",
          "For AMPK-activating compounds where standard oral bioavailability is below 10%, even a modest improvement in delivery efficiency can shift the clinical effect profile significantly. The goal is not to increase the dose but to ensure a larger proportion of each dose reaches its intended metabolic target.",
          "This is why delivery format is not a marketing detail. It is the primary technical variable determining whether a formula produces the effects its compound profile suggests it should.",
        ],
      },
    ],
  },

  "natural-dpp4-inhibition": {
    title: "Natural DPP-4 Inhibition: Extending Your Body's Own GLP-1",
    description:
      "DPP-4 breaks down GLP-1 within minutes of production. Natural compounds with demonstrated DPP-4 inhibitory activity can extend the half-life of endogenous incretins.",
    date: "2026-02-07",
    readTime: "6 min",
    relatedSlugs: ["endogenous-vs-exogenous-glp1", "natural-glp1-activation"],
    sections: [
      {
        heading: "What is DPP-4 and why does it matter?",
        body: [
          "Dipeptidyl peptidase-4 (DPP-4) is a serine protease enzyme that cleaves incretin hormones, including GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). DPP-4 is the primary reason endogenous GLP-1 has a half-life of only about 2 minutes. The hormone is produced, exerts a brief effect, and is rapidly degraded.",
          "This rapid degradation is a normal physiological process. It prevents sustained hormonal signaling from a single meal and maintains tight control over insulin secretion and appetite regulation. But it also means that any strategy to boost natural GLP-1 production faces a clearance problem: even if you increase GLP-1 secretion, the additional hormone is broken down almost as fast as it is produced.",
          "Pharmaceutical companies recognized this limitation early. The DPP-4 inhibitor drug class (sitagliptin, saxagliptin, linagliptin) was developed specifically to slow GLP-1 degradation, extending the effective window of endogenously produced incretins. These drugs are widely prescribed for type 2 diabetes.",
        ],
      },
      {
        heading: "Natural compounds with DPP-4 inhibitory activity",
        body: [
          "Research has identified several naturally occurring compounds with demonstrated DPP-4 inhibitory activity in vitro. These include certain flavonoids, polyphenols, and bioactive peptides derived from food sources.",
          "The mechanism is the same as pharmaceutical DPP-4 inhibitors: competitive or noncompetitive binding to the enzyme's active site, reducing its ability to cleave GLP-1 and GIP. The key difference is potency. Pharmaceutical DPP-4 inhibitors are designed for high-affinity binding and near-complete enzyme inhibition. Natural compounds typically show moderate inhibition at achievable plasma concentrations.",
          "Moderate inhibition is not clinically irrelevant. A partial reduction in DPP-4 activity can meaningfully extend the functional half-life of GLP-1, particularly when combined with strategies that simultaneously increase GLP-1 production. The combination of increased production and reduced degradation creates a compounding effect on active GLP-1 levels.",
        ],
      },
      {
        heading: "The production-plus-protection strategy",
        body: [
          "The most effective approach to boosting endogenous incretin levels combines two mechanisms: stimulating production and inhibiting degradation. This is analogous to filling a bathtub while simultaneously partially plugging the drain.",
          "In the NutraGLP formula, four active systems stimulate GLP-1 and GIP production through distinct pathways: AMPK activation, insulin receptor sensitization, and GPR120 activation. Natural DPP-4 inhibitors then extend the half-life of the newly produced incretins by slowing enzymatic breakdown.",
          "Neither mechanism alone achieves the same result as the combination. Increasing production without addressing degradation results in a brief spike that DPP-4 quickly clears. Inhibiting DPP-4 without increasing production only extends the baseline level. The combination amplifies both the peak and duration of endogenous GLP-1 activity.",
        ],
      },
      {
        heading: "How natural DPP-4 inhibition differs from pharmaceutical DPP-4 inhibitors",
        body: [
          "Pharmaceutical DPP-4 inhibitors (gliptins) achieve 70-90% enzyme inhibition at therapeutic doses. Natural compounds typically achieve more modest inhibition levels. This difference in potency is significant and should not be understated.",
          "The trade-off is in the risk-benefit profile. Pharmaceutical DPP-4 inhibitors carry risks including pancreatitis, joint pain, and potential immunosuppressive effects related to DPP-4's role in immune function. Natural DPP-4 inhibitors, at the concentrations achievable through oral supplementation, are associated with fewer adverse effects.",
          "The appropriate framing is not that natural DPP-4 inhibition replaces pharmaceutical inhibition. It is that partial DPP-4 inhibition, combined with enhanced GLP-1 production, provides a complementary metabolic support strategy with a different risk-benefit profile than pharmaceutical intervention.",
        ],
      },
    ],
  },

  "endogenous-vs-exogenous-glp1": {
    title: "Endogenous vs. Exogenous GLP-1: Two Approaches to the Same Pathway",
    description:
      "Pharmaceutical GLP-1 drugs inject synthetic peptides. Endogenous activation amplifies hormones the gut already produces. Different mechanisms, different risk-benefit profiles, same biological target.",
    date: "2026-01-30",
    readTime: "9 min",
    relatedSlugs: ["natural-dpp4-inhibition", "nanoemulsion-vs-capsules"],
    sections: [
      {
        heading: "The GLP-1 pathway",
        body: [
          "GLP-1 (glucagon-like peptide-1) is an incretin hormone that plays a central role in glucose homeostasis, appetite regulation, and metabolic function. It is produced by L-cells in the distal small intestine and colon in response to nutrient intake. Once secreted, GLP-1 acts on receptors in the pancreas (stimulating insulin secretion), the brain (reducing appetite and food intake), and the GI tract (slowing gastric emptying).",
          "The discovery that GLP-1 receptor activation could produce significant weight loss transformed the pharmaceutical landscape. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become among the most prescribed and discussed drugs in the world, generating tens of billions in annual revenue.",
          "What is sometimes lost in the conversation is that GLP-1 is not a pharmaceutical invention. It is an endogenous hormone. The drugs work by introducing synthetic versions of it at supraphysiological concentrations. The alternative approach, endogenous activation, works by amplifying the body's own production.",
        ],
      },
      {
        heading: "How exogenous GLP-1 drugs work",
        body: [
          "Exogenous GLP-1 receptor agonists (GLP-1 RAs) are synthetic peptides engineered to mimic natural GLP-1 while resisting degradation by the DPP-4 enzyme. Semaglutide, for example, has structural modifications that extend its half-life from 2 minutes (natural GLP-1) to approximately 7 days, enabling once-weekly dosing.",
          "These drugs achieve GLP-1 receptor activation at concentrations far above what the body produces naturally. This supraphysiological stimulation produces pronounced effects: significant appetite suppression, slowed gastric emptying, improved glycemic control, and in many patients, substantial weight loss (15-20% of body weight in clinical trials).",
          "The potency of exogenous GLP-1 is also the source of its side effect profile. Nausea, vomiting, diarrhea, and constipation are common, particularly during dose titration. More serious but less common concerns include pancreatitis, gallbladder disease, and reports of muscle mass loss accompanying fat loss. The long-term effects of sustained supraphysiological GLP-1 receptor activation are still being studied.",
        ],
      },
      {
        heading: "How endogenous GLP-1 activation works",
        body: [
          "Endogenous activation takes a fundamentally different approach. Rather than introducing synthetic peptides from outside the body, it aims to increase the production and extend the half-life of the GLP-1 your gut already makes.",
          "This involves two parallel strategies. First, stimulating L-cell secretion of GLP-1 through compounds that activate known production pathways, including AMPK activation, GPR120 receptor activation, and insulin receptor sensitization. Second, inhibiting DPP-4, the enzyme that degrades GLP-1, to extend the window each molecule of endogenous GLP-1 remains active.",
          "The endogenous approach works within the body's existing feedback mechanisms. Natural GLP-1 production is regulated by nutrient intake, hormonal feedback loops, and neural signaling. Amplifying this production increases the signal within the system's normal operating parameters, rather than overriding the system with external input.",
        ],
      },
      {
        heading: "Comparing the two approaches",
        body: [
          "The key distinction is concentration and control. Exogenous GLP-1 drugs deliver the hormone at concentrations many times higher than the body produces naturally, and the effect persists for days due to engineered resistance to degradation. Endogenous activation increases production and extends half-life within a range closer to the body's natural capacity.",
          "This means the exogenous approach is more powerful in absolute terms. The clinical data on semaglutide and tirzepatide show effects that no supplement can replicate. If maximizing weight loss is the sole objective and the risk-benefit analysis supports it, pharmaceutical GLP-1 drugs are the more potent tool.",
          "The endogenous approach offers a different value proposition. It is non-prescription, non-injectable, and works within physiological ranges. For individuals who do not qualify for or do not want pharmaceutical GLP-1 therapy, or who are looking for metabolic support rather than maximum pharmacological intervention, endogenous activation provides a complementary option.",
          "It is important to state clearly: endogenous GLP-1 activation is not a replacement for prescribed GLP-1 medication. The two approaches target the same pathway through different mechanisms with different magnitudes of effect. They occupy different positions on the intervention spectrum.",
        ],
      },
      {
        heading: "The bioavailability variable",
        body: [
          "One factor that has historically limited endogenous activation strategies is bioavailability. AMPK-activating compounds have strong clinical evidence for GLP-1 stimulation but poor oral absorption in standard formats. The gap between what the research shows and what consumers experience is largely a delivery problem.",
          "Nanoemulsion technology addresses this by encapsulating active compounds in lipid-based nanoparticles that increase absorption across the intestinal epithelium. The effect is not to make endogenous activation equivalent to pharmaceutical intervention, but to ensure that the compounds known to stimulate GLP-1 production actually reach their target pathways at effective concentrations.",
          "When delivery is optimized, the endogenous activation thesis becomes testable in a way it was not with standard supplement formats. The compounds have published evidence. The pathways are well-characterized. The remaining variable was whether they could be delivered effectively. That is the problem nanoemulsion solves.",
        ],
      },
    ],
  },
};

export async function generateStaticParams() {
  return Object.keys(articles).map((slug) => ({ slug }));
}

export async function generateMetadata({
  params,
}: {
  params: Promise<{ slug: string }>;
}): Promise<Metadata> {
  const { slug } = await params;
  const article = articles[slug];
  if (!article) return {};
  return {
    title: article.title,
    description: article.description,
    alternates: {
      canonical: `https://nutraglp.com/blog/${slug}`,
    },
  };
}

export default async function BlogPost({
  params,
}: {
  params: Promise<{ slug: string }>;
}) {
  const { slug } = await params;
  const article = articles[slug];
  if (!article) notFound();

  const articleSchema = {
    "@context": "https://schema.org",
    "@type": "Article",
    headline: article.title,
    description: article.description,
    datePublished: article.date,
    url: `https://nutraglp.com/blog/${slug}`,
    publisher: {
      "@type": "Organization",
      name: "NutraGLP",
      url: "https://nutraglp.com",
    },
    mainEntityOfPage: {
      "@type": "WebPage",
      "@id": `https://nutraglp.com/blog/${slug}`,
    },
  };

  return (
    <main>
      <script
        type="application/ld+json"
        dangerouslySetInnerHTML={{ __html: JSON.stringify(articleSchema) }}
      />

      {/* Hero */}
      <section className="bg-forest-deep px-6 md:px-12 pt-28 pb-20">
        <div className="max-w-[720px] mx-auto">
          <Link
            href="/blog"
            className="text-[11px] font-bold uppercase tracking-[2px] text-gold no-underline hover:text-gold-light transition"
          >
            &larr; Research &amp; Insights
          </Link>
          <h1
            className="text-3xl md:text-[42px] font-normal text-white leading-[1.12] tracking-tight mt-6 mb-6"
            style={{ fontFamily: "'Fraunces', Georgia, serif" }}
          >
            {article.title}
          </h1>
          <div className="flex items-center gap-4">
            <time className="text-sm text-white/40">
              {new Date(article.date).toLocaleDateString("en-US", {
                month: "long",
                day: "numeric",
                year: "numeric",
              })}
            </time>
            <span className="text-white/20">&middot;</span>
            <span className="text-sm text-white/40">{article.readTime} read</span>
          </div>
        </div>
      </section>

      {/* Article body */}
      <article className="py-16 px-6 md:px-12">
        <div className="max-w-[720px] mx-auto space-y-12">
          {article.sections.map((section) => (
            <div key={section.heading}>
              <h2
                className="text-xl md:text-2xl font-normal tracking-tight leading-tight mb-5 text-ink"
                style={{ fontFamily: "'Fraunces', Georgia, serif" }}
              >
                {section.heading}
              </h2>
              <div className="space-y-4">
                {section.body.map((paragraph, i) => (
                  <p
                    key={i}
                    className="text-[16px] leading-[1.75] text-mist"
                  >
                    {paragraph}
                  </p>
                ))}
              </div>
            </div>
          ))}
        </div>
      </article>

      {/* Related reading */}
      {article.relatedSlugs.length > 0 && (
        <section className="py-12 px-6 md:px-12">
          <div className="max-w-[720px] mx-auto">
            <p className="text-[11px] font-bold uppercase tracking-[2px] text-forest-mid mb-6">
              Related reading
            </p>
            <div className="space-y-4">
              {article.relatedSlugs.map((rs) => {
                const related = articles[rs];
                if (!related) return null;
                return (
                  <Link
                    key={rs}
                    href={`/blog/${rs}`}
                    className="block p-5 bg-white border border-rule rounded-lg hover:border-forest-mid/40 transition no-underline"
                  >
                    <p
                      className="text-[17px] font-normal tracking-tight text-ink mb-1"
                      style={{ fontFamily: "'Fraunces', Georgia, serif" }}
                    >
                      {related.title}
                    </p>
                    <p className="text-sm text-mist leading-relaxed line-clamp-2">
                      {related.description}
                    </p>
                  </Link>
                );
              })}
            </div>
          </div>
        </section>
      )}

      <hr className="max-w-[720px] mx-auto border-t border-rule" />

      {/* Cross-links */}
      <section className="py-12 px-6 md:px-12">
        <div className="max-w-[720px] mx-auto flex flex-wrap gap-6">
          <Link
            href="/blog"
            className="text-sm text-forest-mid hover:text-forest transition no-underline border-b border-forest-mid/30 pb-0.5"
          >
            All articles &rarr;
          </Link>
          <Link
            href="/science"
            className="text-sm text-forest-mid hover:text-forest transition no-underline border-b border-forest-mid/30 pb-0.5"
          >
            Full science breakdown &rarr;
          </Link>
          <Link
            href="/slim-shot"
            className="text-sm text-forest-mid hover:text-forest transition no-underline border-b border-forest-mid/30 pb-0.5"
          >
            Slim SHOT product details &rarr;
          </Link>
        </div>
      </section>

      {/* CTA */}
      <section className="bg-forest py-20 px-6 md:px-12 text-center">
        <h2
          className="text-3xl md:text-4xl font-normal text-white tracking-tight mb-4"
          style={{ fontFamily: "'Fraunces', Georgia, serif" }}
        >
          Ready to try a different approach?
        </h2>
        <p className="text-[17px] text-white/50 max-w-[520px] mx-auto mb-8">
          $145/mo. No prescription. No commitment. Join the waitlist for
          early access and launch pricing.
        </p>
        <WaitlistForm variant="cta" />
      </section>

      <Footer />
    </main>
  );
}
